James Quigley
Stock Analyst at Goldman Sachs
(1.01)
# 3,858
Out of 5,174 analysts
26
Total ratings
33.33%
Success rate
-4.52%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | $63 → $41 | $36.89 | +11.14% | 2 | Mar 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $74.42 | +70.65% | 7 | Dec 9, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $148.61 | -20.60% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $45.14 | +44.00% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $7.60 | +38.16% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $29.80 | +34.23% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $2.34 | +583.76% | 3 | Jun 23, 2023 |
Novo Nordisk
Mar 2, 2026
Downgrades: Neutral
Price Target: $63 → $41
Current: $36.89
Upside: +11.14%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $74.42
Upside: +70.65%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $148.61
Upside: -20.60%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $45.14
Upside: +44.00%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $7.60
Upside: +38.16%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $29.80
Upside: +34.23%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $2.34
Upside: +583.76%